Advertisement

Minimal Residual Disease in Acute Leukemia 1986

  • Anton Hagenbeek
  • Bob Löwenberg

Part of the Developments in Oncology book series (DION, volume 45)

Table of contents

  1. Front Matter
    Pages I-XIV
  2. Detection of Minimal Residual Disease in Acute Leukemia

    1. A. Hagemeijer, H. J. Adriaansen, C. R. Bartram
      Pages 1-11
    2. G. C. Grosveld, D. Bootsma, A. de Klein, N. Heisterkamp, K. Stam, J. Groffen
      Pages 12-22
    3. J. L. Bos, M. Verlaan-de Vries, A. J. van der Eb, R. Delwel, B. Löwenberg, S. J. Roodenhuis et al.
      Pages 43-50
    4. J. J. Wright, D. G. Poplack, A. Bakhshi, S. J. Korsmeyer
      Pages 51-57
    5. J. J. M. van Dongen, H. Hooijkaas, H. J. Adriaansen, K. Hahlen, G. E. van Zanen
      Pages 113-133
  3. Intensive Chemotherapy Regimens for ‘Minimal Residual Disease’ in Acute Myeloblastic and Lymphoblastic Leukemia

  4. Autologous Bone Marrow Transplantation for the Eradication of ‘Minimal Residual Leukemia’

  5. Allogeneic Bone Marrow Transplantation for the Eradication of ‘Minimal Residual Leukemia’

    1. G. W. Santos, R. Saral, W. H. Burns, H. G. Braine, L. L. Sensenbrenner, J. R. Wingard et al.
      Pages 305-317
    2. R. P. Witherspoon, C. D. Buckner, E. D. Thomas, H. J. Deeg, K. Sullivan, R. Clift et al.
      Pages 318-322
    3. H. G. Prentice, M. K. Brenner, J.-P. Grob, G. Janossy, J. Wimperis, A. V. Hoffbrand et al.
      Pages 323-336
  6. Summing up

  7. Back Matter
    Pages 389-393

About this book

Introduction

Relapse of leukemia following successful remission-induction therapy remains a major obstacle in the treatment of patients with acute leukemia. Leukemia recurs most frequently in patients with acute myeloblastic leukemia (AML) and high risk acute lymphoblastic leukemia (ALL) following chemotherapy and less often in patients with low risk ALL and particularly in patient groups> submitted to allogeneic marrow transplantation. ' It is likely that the great majority of these recurrences originate from residual leukemic cells that survive initial remission-induction chemotherapy. Today, several research groups throughout the world place emphasis on studies concerned with the detection and treatment of 'minimal residual disease' (MRD). These investigations are conducted with the common objective to tackle the remaining cells. 'Minimal Residual Disease in Acute Leukemia: 1986' summarizes the fast advancements in this area. Several disciplines are concerned with the analysis of leukemic cells. The perspectives of cytogenetic and molecular genetic approaches for applica­ tion in the detection of MRD are reviewed. In this respect, modern cyto­ genetics provide highly specific tumor markers. The resolution of cyto­ genetic methods can be particularly improved when combined with other techniques which select relevant subpopulations of cells. Characterization of oncogenes and gene rearrangements, including those of immunoglobulin and T-cell receptor genes, and the measurement of gene products, have been established. Techniques based on these approaches offer interesting tools for the detection of MRD. New possibilities of employing monoclonal anti­ bodies are also presented.

Keywords

DNA blood bone marrow cell chemotherapy classification clinical trial leukemia prevention transplantation tumor

Editors and affiliations

  • Anton Hagenbeek
    • 1
    • 2
  • Bob Löwenberg
    • 1
  1. 1.The Dr. Daniël den Hoed Cancer CenterRotterdamThe Netherlands
  2. 2.Radiobiological Institute TNORijswijkThe Netherlands

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-009-4273-8
  • Copyright Information Springer Science+Business Media B.V. 1986
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-010-8398-0
  • Online ISBN 978-94-009-4273-8
  • Buy this book on publisher's site